Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) EBIT (2016 - 2025)

Historic EBIT for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to -$2.0 million.

  • Aytu Biopharma's EBIT fell 1622.42% to -$2.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$8.7 million, marking a year-over-year decrease of 2249.05%. This contributed to the annual value of -$7.8 million for FY2025, which is 25920.15% down from last year.
  • Per Aytu Biopharma's latest filing, its EBIT stood at -$2.0 million for Q4 2025, which was down 1622.42% from -$1.5 million recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's EBIT ranged from a high of $3.1 million in Q4 2023 and a low of -$53.4 million during Q1 2022
  • Its 5-year average for EBIT is -$9.5 million, with a median of -$2.4 million in 2024.
  • Its EBIT has fluctuated over the past 5 years, first tumbled by 179289.94% in 2024, then skyrocketed by 25159.67% in 2025.
  • Aytu Biopharma's EBIT (Quarter) stood at -$11.3 million in 2021, then skyrocketed by 39.19% to -$6.9 million in 2022, then skyrocketed by 145.81% to $3.1 million in 2023, then crashed by 153.88% to -$1.7 million in 2024, then dropped by 16.22% to -$2.0 million in 2025.
  • Its EBIT stands at -$2.0 million for Q4 2025, versus -$1.5 million for Q3 2025 and -$7.6 million for Q2 2025.